Small molecules targeting the intrinsically disordered structural ensemble of α-synuclein protect against diverse α-synuclein mediated dysfunctions
AssigneesThe Regents of the University of California, Dainton Biosciences, LLC
InventorsLisa McConlogue, David A. Agard
Life of this patent
Estimating the term…
Abstract
Provided herein are pharmaceutical compositions and methods for treatment or prevention of synucleinopathies with small-molecule inhibitors of pathogenic α-synuclein activity having the Formula (I). Also, provide are methods for identifying novel compounds for modulating α-synuclein activity.
Claims5
A method for treating or preventing synucleinopathy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a small-molecule inhibitor of pathogenic α-synuclein activity, wherein the small-molecule inhibitor is:
- 2-amino-5-hydroxy-N-methylbenzamide, 2-methylamino-5-hydroxy-N-methylbenzamide, 2-dimethylamino-5-hydroxy-N-methylbenzamide, 2,5-dihydroxy-N-methylbenzamide, or any combination thereof.
A method of inhibiting α-synuclein oligomerization or α-synuclein inhibition of vesicular dynamics, comprising contacting α-synuclein monomers with a small-molecule selected from the group consisting of 2-amino-5-hydroxy-N-methylbenzamide, 2-methylamino-5-hydroxy-N-methylbenzamide, 2-dimethylamino-5-hydroxy-N-methylbenzamide, 2,5-dihydroxy-N-methylbenzamide, and any combination thereof.
Dependencies are inferred from the claim text.